Compare · LGVN vs NVO
LGVN vs NVO
Side-by-side comparison of Longeveron Inc. (LGVN) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LGVN and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 11336.8x LGVN ($19.7M).
- Over the past year, LGVN is down 59.4% and NVO is down 21.8% - NVO leads by 37.6 points.
- LGVN has been more active in the news (15 items in the past 4 weeks vs 5 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 2 for LGVN).
- Company
- Longeveron Inc.
- Novo Nordisk A/S
- Price
- $0.62-0.48%
- $50.31-2.25%
- Market cap
- $19.7M
- $222.81B
- 1M return
- -21.32%
- +15.47%
- 1Y return
- -59.37%
- -21.78%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 15
- 5
- Recent ratings
- 2
- 25
Longeveron Inc.
Longeveron Inc., a clinical stage biotechnology company, engages in developing cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications comprising aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest LGVN
- New insider Desai Arjun Jj claimed no ownership of stock in the company (SEC Form 3)
- Longeveron Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- New insider Ascheim Deborah claimed no ownership of stock in the company (SEC Form 3)
- New insider Cann Leah Rush claimed no ownership of stock in the company (SEC Form 3)
- Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer’s Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer’s Disease
- SEC Form S-8 filed by Longeveron Inc.
- Chief Scientific Officer Hare Joshua was granted 600,000 units of Class B Common Stock, increasing direct ownership by 83% to 1,321,796 units (SEC Form 4)
- Longeveron Inc. filed SEC Form 8-K: Leadership Update
- Chief Executive Officer Willard Stephen H covered exercise/tax liability with 18,046 shares, decreasing direct ownership by 2% to 771,681 units (SEC Form 4) (tax liability)
- Chief Financial Officer Locklear Lisa covered exercise/tax liability with 22,505 shares, decreasing direct ownership by 5% to 443,181 units (SEC Form 4) to satisfy tax liability
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S